| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Department of Rheumatology, University Hospital, Nijmegen, The Netherlands.
An investigation of clinical and laboratory variables which might form the basis for judging disease activity in clinical practice was made by six rheumatologists in a prospective study of up to three years' duration of 113 patients with early rheumatoid arthritis. Decisions to start treatment with slow acting antirheumatic drugs were equated with moments of high disease activity. If treatment with slow acting antirheumatic drugs was not started or if the slow acting antirheumatic drug remained unchanged for at least one year or if treatment was stopped because of disease remission, this was equated with periods of low disease activity. Two groups, one with high and one with low disease activity according to the above criteria, were formed. Factor analysis was performed to enable easy handling of the large number of clinical and laboratory variables without loss of information; this resulted in five factors. Next, discriminant analysis was done to determine to what extent each factor contributed to discrimination between the two groups of differing disease activity. Finally, a multiple regression analysis was carried out to determine which laboratory and clinical variables underlie the factors of the discriminant function, resulting in a 'disease activity score'. This score consisted of the following variables: Ritchie index, swollen joints, erythrocyte sedimentation rate, and general health, in declining importance. The rheumatologists' decisions to prescribe slow acting antirheumatic drugs, or not, were mainly based on articular symptoms.
This article has been cited by other articles:
|
|
 |
|
  E Tanaka, A Mannalithara, E Inoue, M Hara, T Tomatsu, N Kamatani, G Singh, and H Yamanaka Efficient management of rheumatoid arthritis significantly reduces long-term functional disability Ann Rheum Dis, August 1, 2008; 67(8): 1153 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Smith, T. Ding, S. Butt, K. Gadsby, and C. Deighton The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice Rheumatology, July 4, 2008; (2008) ken233v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pincus, M. J. Bergman, Y. Yazici, P. Hines, K. Raghupathi, and R. Maclean An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures Rheumatology, March 1, 2008; 47(3): 345 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Scott and D. P. M. Symmons The role of specialists in managing established rheumatoid arthritis Rheumatology, March 1, 2008; 47(3): 237 - 238. [Full Text] [PDF]
|
|
|
|
|
|
S. Jerram, S. Butt, K. Gadsby, and C. Deighton Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern? Rheumatology, February 1, 2008; 47(2): 180 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Furst, R. J. Halbert, C. O. Bingham III, S. Fukudome, L. Anderson, P. Bonafede, V. Bray, S. B. Cohen, Y. R. S. Sherrer, E. W. S. St Clair, et al. Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel Rheumatology, February 1, 2008; 47(2): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Salaffi, E. Filippucci, M. Carotti, E. Naredo, G. Meenagh, A. Ciapetti, V. Savic, and W. Grassi Inter-observer agreement of standard joint counts in early rheumatoid arthritis: a comparison with grey scale ultrasonography a preliminary study Rheumatology, January 1, 2008; 47(1): 54 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K Ranganath, J. Yoon, D. Khanna, G. S Park, D. E Furst, D. A Elashoff, D. Jawaheer, J. T Sharp, R. H Gold, E. C Keystone, et al. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort Ann Rheum Dis, December 1, 2007; 66(12): 1633 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F M McQueen, A Gao, M Ostergaard, A King, G Shalley, E Robinson, A Doyle, B Clark, and N Dalbeth High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone Ann Rheum Dis, December 1, 2007; 66(12): 1581 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsui, Y. Kuga, A. Kaneko, J. Nishino, Y. Eto, N. Chiba, M. Yasuda, K. Saisho, K. Shimada, and S. Tohma Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan Ann Rheum Dis, September 1, 2007; 66(9): 1221 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mikuls The treatment of lymphoma complicating autoimmune disease: two birds with one stone? Ann. Onc., April 1, 2007; 18(4): 615 - 618. [Full Text] [PDF]
|
|
|
|
|
|
E. Inoue, H. Yamanaka, M. Hara, T. Tomatsu, and N. Kamatani Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values Ann Rheum Dis, March 1, 2007; 66(3): 407 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Cohen, L Gossec, M Dougados, A Cantagrel, P Goupille, J. Daures, N Rincheval, and B Combe Radiological damage in patients with rheumatoid arthritis on sustained remission Ann Rheum Dis, March 1, 2007; 66(3): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Park, Weng Kee Wong, M. Oh, D. Khanna, R. H. Gold, J. T. Sharp, and H. E. Paulus Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences Statistical Methods in Medical Research, February 1, 2007; 16(1): 13 - 29. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Borras-Blasco, C. Nunez-Cornejo, A. Gracia-Perez, J D. Rosique-Robles, M. E. Castera, E. Viosca, and F J. Abad Parapharyngeal Abscess in a Patient Receiving Etanercept Ann. Pharmacother., February 1, 2007; 41(2): 341 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A Capell, R. Madhok, D. R Porter, R. A L Munro, I. B McInnes, J. A Hunter, M. Steven, A. Zoma, E. Morrison, M. Sambrook, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study Ann Rheum Dis, February 1, 2007; 66(2): 235 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Young, G. Koduri, M. Batley, E. Kulinskaya, A. Gough, S. Norton, J. Dixey, and on behalf of the Early Rheumatoid Arthritis Study Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis Rheumatology, February 1, 2007; 46(2): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Fransen, C Antoni, P J Mease, W Uter, A Kavanaugh, J R Kalden, and P L C M Van Riel Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors Ann Rheum Dis, October 1, 2006; 65(10): 1373 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Pincus, T Sokka, C P Chung, and G Cawkwell Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials Ann Rheum Dis, July 1, 2006; 65(7): 878 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J van Aken, H van Dongen, S le Cessie, C F Allaart, F C Breedveld, and T W J Huizinga Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study Ann Rheum Dis, January 1, 2006; 65(1): 20 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Noguera-Pons, J. Borras-Blasco, I. Romero-Crespo, R. Anton-Torres, A. Navarro-Ruiz, and J. A. Gonzalez-Ferrandez Optic Neuritis with Concurrent Etanercept and Isoniazid Therapy Ann. Pharmacother., December 1, 2005; 39(12): 2131 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P L C M van Riel and J Fransen To be in remission or not: is that the question? Ann Rheum Dis, October 1, 2005; 64(10): 1389 - 1390. [Full Text] [PDF]
|
|
|
|
|
|
H Makinen, H Kautiainen, P Hannonen, and T Sokka Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis, October 1, 2005; 64(10): 1410 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Trieb Management of the foot in rheumatoid arthritis J Bone Joint Surg Br, September 1, 2005; 87-B(9): 1171 - 1177. [Full Text] [PDF]
|
|
|
|
|
|
J J C S Veldhuijzen van Zanten, C Ring, D Carroll, and G D Kitas Increased C reactive protein in response to acute stress in patients with rheumatoid arthritis Ann Rheum Dis, September 1, 2005; 64(9): 1299 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Gulfe, P Geborek, and T Saxne Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis, August 1, 2005; 64(8): 1186 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ralph, A. N. McEvoy, D. Kane, B. Bresnihan, O. FitzGerald, and E. P. Murphy Modulation of Orphan Nuclear Receptor NURR1 Expression by Methotrexate in Human Inflammatory Joint Disease Involves Adenosine A2A Receptor-Mediated Responses J. Immunol., July 1, 2005; 175(1): 555 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M M Eijsbouts, F H J van den Hoogen, R F J M Laan, C G J Sweep, A R M M Hermus, and L B A van de Putte Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity Ann Rheum Dis, March 1, 2005; 64(3): 433 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J Mease, C E Antoni, D D Gladman, and W J Taylor Psoriatic arthritis assessment tools in clinical trials Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii49 - ii54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Dougados, P Emery, E M Lemmel, C A F Zerbini, S Brin, and P van Riel When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis, January 1, 2005; 64(1): 44 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Pincus and T Sokka Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii32 - ii39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fransen, M. C. W. Creemers, and P. L. C. M. Van Riel Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria Rheumatology, October 1, 2004; 43(10): 1252 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F M van Dunne, L R Lard, D Rook, F M Helmerhorst, and T W J Huizinga Miscarriage but not fecundity is associated with progression of joint destruction in rheumatoid arthritis Ann Rheum Dis, August 1, 2004; 63(8): 956 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Miranda-Carus, A. Balsa, M. Benito-Miguel, C. Perez de Ayala, and E. Martin-Mola IL-15 and the Initiation of Cell Contact-Dependent Synovial Fibroblast-T Lymphocyte Cross-Talk in Rheumatoid Arthritis: Effect of Methotrexate J. Immunol., July 15, 2004; 173(2): 1463 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. K. Nell, K. P. Machold, G. Eberl, T. A. Stamm, M. Uffmann, and J. S. Smolen Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis Rheumatology, July 1, 2004; 43(7): 906 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L B A van de Putte, C Atkins, M Malaise, J Sany, A S Russell, P L C M van Riel, L Settas, J W Bijlsma, S Todesco, M Dougados, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis, May 1, 2004; 63(5): 508 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Benton, N Stewart, J Crabbe, E Robinson, S Yeoman, and F M McQueen MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years Ann Rheum Dis, May 1, 2004; 63(5): 555 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. James, A. Young, E. Kulinskaya, E. Knight, W. Thompson, W. Ollier, and J. Dixey Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years Rheumatology, March 1, 2004; 43(3): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Tchetverikov, L R Lard, J DeGroot, N Verzijl, J M TeKoppele, F C Breedveld, T W J Huizinga, and R Hanemaaijer Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis Ann Rheum Dis, November 1, 2003; 62(11): 1094 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Barrera, W J G Oyen, O C Boerman, and P L C M van Riel Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis Ann Rheum Dis, September 1, 2003; 62(9): 825 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Scott, C. Antoni, E. H. Choy, and P. C. L. M. van Riel Joint counts in routine practice Rheumatology, August 1, 2003; 42(8): 919 - 923. [Full Text] [PDF]
|
|
|
|
|
|
P A Klimiuk, S Sierakowski, R Latosiewicz, J P Cylwik, B Cylwik, J Skowronski, and J Chwiecko Circulating tumour necrosis factor {alpha} and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis Ann Rheum Dis, May 1, 2003; 62(5): 472 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Barber, T Sheeran, and D Mulherin Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis Ann Rheum Dis, May 1, 2003; 62(5): 490 - 491. [Full Text]
|
|
|
|
|
|
J. S. Smolen, F. C. Breedveld, M. H. Schiff, J. R. Kalden, P. Emery, G. Eberl, P. L. van Riel, and P. Tugwell A simplified disease activity index for rheumatoid arthritis for use in clinical practice Rheumatology, February 1, 2003; 42(2): 244 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E van Ede, R F J M Laan, R A De Abreu, A B J Stegeman, and L B A van de Putte Purine enzymes in patients with rheumatoid arthritis treated with methotrexate Ann Rheum Dis, December 1, 2002; 61(12): 1060 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Carotti, F Salaffi, P Manganelli, D Salera, B Simonetti, and W Grassi Power Doppler sonography in the assessment of synovial tissue of the knee joint in rheumatoid arthritis: a preliminary experience Ann Rheum Dis, October 1, 2002; 61(10): 877 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. van Ede, R. F. J. M. Laan, H. J. Blom, G. H. J. Boers, C. J. Haagsma, C. M. G. Thomas, T. M. de Boo, and L. B. A. van de Putte Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis Rheumatology, June 1, 2002; 41(6): 658 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K W Drossaers-Bakker, A H Zwinderman, D van Zeben, F C Breedveld, and J M W Hazes Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis Ann Rheum Dis, May 1, 2002; 61(5): 405 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A A den Broeder, L A B Joosten, T Saxne, D Heinegard, H Fenner, A M M Miltenburg, W L H Frasa, L J van Tits, W A Buurman, P L C M van Riel, et al. Long term anti-tumour necrosis factor {alpha} monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis, April 1, 2002; 61(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Young, J Dixey, E Kulinskaya, N Cox, P Davies, J Devlin, P Emery, A Gough, D James, P Prouse, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS) Ann Rheum Dis, April 1, 2002; 61(4): 335 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E T H Molenaar, A E Voskuyl, I E van der Horst-Bruinsma, G M T. Schreuder, E Zanelli, and B A C Dijkmans Influence of HLA polymorphism on persistent remission in rheumatoid arthritis Ann Rheum Dis, April 1, 2002; 61(4): 351 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barrera, A. van der Maas, A. E. van Ede, B. A. L. M. Kiemeney, R. F. J. M. Laan, L. B. A. van de Putte, and P. L. C. M. van Riel Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-{alpha} antibody compared with methotrexate in long-standing rheumatoid arthritis Rheumatology, April 1, 2002; 41(4): 430 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Verhoeven, M. Boers, J. M. te Koppele, W. H. van der Laan, H. M. Markusse, P. Geusens, and S. van der Linden Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone Rheumatology, November 1, 2001; 40(11): 1231 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Barrera, L A B Joosten, A A den Broeder, L B A van de Putte, P L C M van Riel, and W B van den Berg Effects of treatment with a fully human anti-tumour necrosis factor {alpha} monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF{alpha} in patients with rheumatoid arthritis Ann Rheum Dis, July 1, 2001; 60(7): 660 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M C Albers, L Paimela, P Kurki, K B Eberhardt, P Emery, M A van `t Hof, F H J M Schreuder, M Leirisalo-Repo, and P L C M van Riel Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis Ann Rheum Dis, May 1, 2001; 60(5): 453 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
|
